Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Expedia Group Inc (EXPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Expedia Group Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $35.45 (market cap $4.59B), while Expedia Group Inc trades at $269.5 (market cap $32.42B). The key difference: Expedia Group Inc is far larger — about 7.1× Definium Therapeutics Inc. Common Shares's market cap, and Expedia Group Inc pays a 0.71% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Expedia Group Inc for 48 Days on average.
| DFTX | EXPE | |
|---|---|---|
Market Cap | $4.59B | $32.42B |
Volume | 2,103,937 | 1,940,671 |
Sector | Health | Consumer Cyclical |
52-Week High | $48.45 | $339.13 |
52-Week Low | $10.68 | $188.51 |
Typical Hold Time | 0 Days | 48 Days |
Enterprise Value | $3.55B | $30.98B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Expedia Group (EXPE) trades at $258.86, down 0.38% on the day, with technical indicators showing bearish momentum as the stock tests key support levels. Fundamentally, the company demonstrates strong revenue growth from $14.73B in 2025 to projected $15.7B in 2026, with net income margins improving to 12.97%. Recent earnings beats and a 47.37% analyst buy rating support the positive outlook, though competition from AI travel agents presents headwinds.
The stock offers significant upside to the $335.06 consensus price target, representing 29% potential appreciation. Strong cash flow generation and improving profitability metrics support the bullish case, but investors must monitor competitive threats from AI disruption and recent layoffs indicating operational challenges. The current valuation at 16.28 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
